摘要
目的:研究微小染色体维持蛋白7 (MCM7)和肿瘤相关钙信号转导蛋白2 (TACSTD2)在甲状腺乳头状癌(PTC)中的表达及临床意义。方法:采用免疫组化方法对109例甲状腺良恶性病变(甲状腺乳头状癌69例、结节性甲状腺肿组织40例、癌旁甲状腺组织69例)中MCM7和TACSTD2的表达进行检测。结果:MCM7在上述组织中的阳性表达率分别为97.1% (67/69)、65.0% (26/40)和15.94% (11/69),TACSTD2在上述组织的阳性表达率分别为98.55% (68/69)、60.0% (24/40)和17.39% (12/69)。两种蛋白在上述三种组织的阳性表达率差异均具有统计学意义(c2 = 94.5 P c2 = 93.6, P P P = 0.016, Objective: To investigate the expression and clinical significance of minosomal maintenance protein 7 (MCM7) and tumor-associated calcium signal transducer 2 (TACSTD2) in papillary thyroid carcinoma (PTC). Methods: Immunohistochemistry was used to detect the expression of MCM7 and TACSTD2 in 109 cases of benign and malignant thyroid lesions (69 cases of papillary thyroid carcinoma, 40 cases of nodular goiter and 69 cases of adjacent thyroid tissues). Results: The positive expression rates of MCM7 in the above tissues were 97.1% (67/69), 65.0% (26/40) and 15.94% (11/69), respectively. The positive expression rates of TACSTD2 in the above tissues were 98.55% (68/69), 60.0% (24/40) and 17.39% (12/69), respectively. The positive expression rates of the two proteins in the above three tissues were statistically significant (c2 = 94.5, P c2 = 93.6, P P P = 0.016, < 0.05). Conclusions: MCM7 and TACSTD2 are highly expressed in PTC tissues, and the positive expression of TACSTD2 is positively correlated with tumor diameter, which may be involved in the occurrence and development of PTC. Both of them may provide new molecular biological markers for the diagnosis of PTC.
出处
《临床医学进展》
2024年第8期1018-1026,共9页
Advances in Clinical Medicine